The free trade, foreign policy apparatus on Capitol Hill is openly advocating for the extension of the African Growth and Opportunity Act (AGOA), with senior committee leaders from both parties coming out in favor of it during a March 3 Center for Strategic and International Studies event about the trade deal’s future.
Last year, Americans spent more than $15 billion on Novo Nordisk’s diabetes and weight-loss drugs Ozempic and Wegovy. The active ingredient in both treatments — semaglutide— has rapidly become one of the world’s most commercially successful medicines.
Cheap imports shaved prices on some goods but never made Americans richer. Wage losses and job destruction outweighed any discounts.
On Capitol Hill, the defense narrative clearly gets legislators’ attention. It remains the surest way to get Members of Congress thinking about reindustrialization and rebuilding domestic supply chains.
It was no surprise that the 2025 goods deficit broke another record, the Bureau of Economic Analysis (BEA) numbers showed recently. The year-ending goods deficit was $1.24 trillion, up from $1.21 trillion in 2024, with the monthly deficit for December looking like historic averages, nearly $100 billion. Nothing seems to stop America’s appetite for imports.
For the first time, the new portal provides the American public with detailed access to reported foreign funding, including gifts and contracts from entities designated as “entities of concern” on nine federal government watchlists.
CPA urges the administration to move swiftly to deploy Section 232 investigations through the U.S. Department of Commerce as the most durable and effective tool available to restore American industrial capacity.
President Trump has made American reindustrialization and reshoring central to his economic policy agenda. Reviving American manufacturing enjoys broad public support and has increasingly become a bipartisan priority.
Today’s SCOTUS ruling should encourage the administration to refocus and expand its Section 232 efforts.
The Senate Finance Committee agrees on two things: First, the U.S. Mexico and Canada Agreement (USMCA) isn’t perfect and a number of issues need fixing. Second, they don’t want tariffs.
